A judge handed Thousand Oaks-based biotech giant Amgen a major win Aug. 9 when it permanently blocked sales of a competitor for its blockbuster rheumatoid arthritis drug Enbrel. The ruling in New Jersey District Court holds in place an injunction against Sandoz, a German division of Swiss multinational Novartis, blocking sales of its Enbrel biosimilar…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
